ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

リンシチニブ

Osi-906

HCID 11640390
ノート反応
基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
867160-71-2
標準SMILES
CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1
InChIKey
PKCDDUHJAFVJJB-VLZXCDOPSA-N
分子式
C26H23N5O
平均分子量
421.5 g/mol
単同位体質量
421.19026037

概要

Linsitinib is an imidazopyrazine that is imidazo[1,5-a]pyrazine substituted by 2-phenylquinolin-7-yl, cis-3-hydroxy-3-methylcyclobutyl, and amino groups at positions 1, 3, and 8, respectively. It is dual inhibitor of the IGF-1 receptor and insulin receptor (IC50 = 35 and 75 nM, respectively) that was previously in clinical development for the treatment of cancer and thyroid eye disease. It has a role as an antineoplastic agent, an antimycobacterial drug, an apoptosis inducer and an insulin-like growth factor receptor 1 antagonist. It is a member of cyclobutanes, a member of benzenes, a member of quinolines, a tertiary alcohol, an aromatic amine and an imidazopyrazine.

名称と識別子

優先名称
Osi-906
IUPAC
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
現地名
リンシチニブ
英語名
Linsitinib
分子式
C26H23N5O
分子量
421.49

名称と別名

OSI-906OSI 906RefChem:928309Linsitinib867160-71-2Linsitinib(OSI-906)OSI906OSI-906 (Linsitinib)ASP-7487OSI-906AAKinome_3532Linsitinib (OSI-906)
名称をさらに表示
リンシチニブ3α-[8-アミノ-1-(2-フェニルキノリン-7-イル)イミダゾ[1,5-a]ピラジン-3-イル]-1-メチルシクロブタン-1α-オール(1s,3r)-3-[8-アミノ-1-(2-フェニルキノリン-7-イル)イミダゾ[1,5-a]ピラジン-3-イル]-1-メチルシクロブタン-1-オールCS-190OSI 906AALinsitinib(OSI906)OSI-906 LinsitinibLinsitinib USP/EP/BPLinsitinib (ASP-7487
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-olMFCD12912153C26H23N5OLinsitinib (USAN/INN)15A52GPT8TCHEMBL1091644CHEBI:91402HMS3295G15

データベース識別子

CAS
867160-71-2、867160-72-3
PubChem CID
11640390
DTXSID
DTXSID401007055
ChEMBL
CHEMBL1996234

物性

構造計算による物性

XLogP
4.2
極性表面積
89.3 Ų
水素結合供与体数
2
水素結合受容体数
5
回転可能結合数
3
重原子数
32
形式電荷
0
複雑度
663

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15

物理化学的性質

融点
175 °C · >175°C (dec.)
比重(密度)
1.39 · 1.39
貯蔵温度
-20 °C · -20°C
溶解性
DMSO に可溶 (最大 30 mg/ml)
酸解離定数(Pka)
14.84 · 14.84±0.40(Predicted)
外見
個体
色
黄色
安定性
-20 °C · -20°C の DMSO 溶液で最大 2 か月間保存できます。
InChIKey
PKCDDUHJAFVJJB-VLZXCDOPSA-N
SMILES
[C@]1(C)(O)C[C@H](C2N3C=CN=C(N)C3=C(C3C=C4C(=CC=3)C=CC(C3=CC=CC=C3)=N4)N=2)C1

化学と産業

薬理情報

Pharmacodynamics · 1 件

In laboratory studies of 28 human tumor cell lines, OSI-906 reduced growth of 15 cell lines representative of colorectal, lung, breast, pancreatic, and pediatric tumors and in mouse models. OSI-906 was particularly effective against tumors that are highly IGF-dependent such as colorectal cancers. According to the researchers, OSI-906 not only slowed tumor growth in mice, but decreased the size of some pre-existing tumors.

Mechanism of Action · 1 件

IGF-1R stimulates proliferation, enables onogenic transformation, and suppresses apoptosis. Inhibitors of IGF-1R are expected to have broad utility in oncology since the over-expression of IGF-1R and/or its ligands or the down-regulation of ligand binding proteins occurs in numerous human malignancies including lung, colon, breast, prostate, brain and skin cancers. In addition, signaling through the IGF system has been implicated in protecting tumor cells from apoptosis induced by anti-cancer treatments such as cytotoxic agents and EGFR inhibitors.

応用分野 · 1 件

説明The binding of insulin-like growth factor 1 (IGF-1) to the IGF-1 receptor (IGF-1R) promotes cell growth while inhibiting apoptotic pathways. Overexpression of IGF-1R is found in certain solid tumors and hematologic neoplasias. However, insulin receptor (InsR) signaling can compensate for IGF-1R inhibition. Linsitinib is a dual inhibitor of IGF-1R and InsR kinases (IC50s = 35 and 75 nM, respectively). It also inhibits InsR-related receptor (IC50 = 75 nM) but is without effect (IC50 > 10 μM) against a large panel of other kinases. Linsitinib inhibits proliferation of a variety of tumor cell lines in vitro and has antitumor efficacy in an IGF-1R-driven xenograft mouse model when administered orally. A rapid, non-invasive method to predict the pharmacodynamic response to linsitinib has been reported.

上流・下流製品情報

上流原料

2-フェニル-7-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)キノリン

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
ChEBI
CHEBI:91402
UNII
15A52GPT8T
Nikkaji
J3.288.961A
Cyclobutanol, 3-(8-aMino-1-broMoiMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-, cis-
炭酸ジセシウム
N,N-ジメチルホルムアミド

サプライヤー100 社

上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
南通飞宇生物科技有限公司0513-68819626 15152877458 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
江苏星科元信息科技有限公司400-605-7200 15335295587 · [email protected]
湖北科乐精细化工有限公司027-59101668 19945030958 · [email protected]
上海波以尔化工有限公司[email protected]
西安瑞成医药科技有限责任公司18220540598; 18291828687 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
安耐吉化学&3A(安徽泽升科技有限公司)021-58432009 400-005-6266 · [email protected]
China Kouting Group Limited+86 (21) 5811-6473 5811-6475 · [email protected]
InvivoChem中国13549236410 · [email protected]
嘉兴市艾森化工有限公司0573-85285100 18627885956 · [email protected]
学研惠(武汉)科技有限公司15727060112 · [email protected]
VDM Biochemicals0330-2528181 · [email protected]
常州新星联生物科技有限公司0519-85556579 13376258932 · [email protected]
Zhejiang J&C Biological Technology Co.,Limited+1-2135480471 · [email protected]
上海瀚香生物科技有限公司177-54423994 17754423994 · [email protected]
杭州东帆化学有限公司86-0571-85151182
济南精合医药科技有限公司0531-88811783 · [email protected]
ChemeGen 中国18818260767 · [email protected]
北京伊诺凯科技有限公司15652467323 · [email protected]
南京精瑞久安生物技术有限公司025-58196018 800028039 · [email protected]
成都诺维生物科技有限公司028-81458053 · [email protected] [email protected]
AdooQ BioScience, LLC+1 (866) 930-6790 · [email protected]
Wuhan NCE Biomedical Co.,Ltd.4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
上海偕腾生物科技有限公司+86-021-58975553 · [email protected]
南京杜莱生物技术有限公司025-84699383-8003;025-846993838003-8003 18013301590 · [email protected]
上海将来实业股份有限公司021-61552785 · [email protected]
西安速加医药科技有限公司029-86115547 17791676824 · [email protected]
上海毕得医药科技股份有限公司400-164-7117 18317119277 · [email protected]
上海寰川实业有限公司021-61478794 · [email protected]
南京百鑫德诺生物科技有限公司025-58849295 · [email protected]
广州市慈铭生物科技有限公司020-38082199,29065168,38082986,29878298,29866629,4000192398
上海孚一生物科技有限公司+86 (21) 61124340
凯试(上海)科技有限公司021-50135380 · [email protected]
上海兴默生物技术有限公司+86 13524779951; 13524779951 · [email protected]
合肥纳禾生物科技有限公司0551-65629887 18010855303 · [email protected]
湖北巨胜科技有限公司027-59599241 18871490274 · [email protected]
池州凯隆进出口贸易有限公司[email protected]
上海楼岚生物科技有限公司021-52996696,15000506266 15000506266
西安新诺化学科技有限公司15332490153 · [email protected]
江苏倍达医药科技有限公司0512-63009836 18994340901 · [email protected]
TargetMol中国(陶术生物)021-021-33632979 15002134094 · [email protected]
武汉天植生物技术有限公司18607101326 15172504745 · [email protected]
上海萄普生物医药技术有限公司15900573766 18018507602 · [email protected]
斯派螺(武汉)药物研发有限公司[email protected]
Henan Alfa Chemical Co., Ltd+8618339805032 · [email protected]
开封明仁药业有限公司0371-65741762 · [email protected]